Showing 731-740 of 3244 results for "".
Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Shifting Paradigms on Lentigo Maligna
https://practicaldermatology.com/conferences/maui-derm-2024/shifting-paradigms-on-lentigo-maligna/20255/According to Ashfaq Marghoob, MD, current research supports individualizing treatment of lentigo maligna (LM) based on what is the best therapeutic option, from active surveillance to surgery to radiation to imiquimod.How does chronic AD histopathology evolve from spongiosis-dominant lesions to lichenified, fibrotic plaques?
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/how-does-chronic-ad-histopathology-evolve-from-spongiosis-dominant-lesions-to-lichenified-fibrotic-plaques/48772/Christopher Bunick, MD, FAAD, discusses the roles of the six major cytokines that drive atopic dermatitis pathophysiology: IL-4, IL-13, IL-31, TSLP, IL-22, and IFN-γ.Choosing the Right Wound Dressing
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/choosing-the-right-wound-dressing/33017/Dennis Orgill, MD, PhD, a reconstructive plastic surgeon at Brigham and Women's Hospital in Boston, discusses the importance of choosing the right dressing for wound care at Masterclasses in Dermatology 2025 in Sarasota.SCALE 2024: Dr. Michael Gold Recaps the Show and Previews 2025
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-michael-gold-recaps-show-and-previews-2025/26751/Michael Gold, MD, FAAD, Course Co-Director for Music City SCALE, discusses the growth of the event over the years, highlights from 2024, and what to expect next year.Unmet Needs in Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37140/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, talks about what he feels are the greatest unmet needs in atopic dermatitis.Welcome to the Dermatology Hub: Neuroimmune Network
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/tbd/39772/Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, explains what clinicians can expect from the Dermatology Hub: Neuroimmune Network, a unique editorial platform that will be updated monthly with exciting new content.Addressing Skin Changes During Menopause: An Update
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/addressing-skin-changes-during-menopause-an-update/20220/New York City-based dermatologist Ellen Gendler, MD, shares pearls from her recent talk at the 2023 annual meeting of the Menopause Society including the current thinking on how to address the effects of diminished estrogen on skin.Evaluating GEP Test Options
https://practicaldermatology.com/programs/practical-dermatology/evaluating-gep-test-options/35600/David Cotter, MD, a board-certified dermatologist, discusses what he looks for in a gene expression profile (GEP) test, including the types of clinical evidence that are most important.GEP Testing for Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/series/updates-in-skin-cancer/gep-testing-for-cutaneous-squamous-cell-carcinoma/35599/Emily Ruiz, MD, MPH, FAAD, director of the High-Risk Cancer Clinic at Dana-Farber Cancer Institute, discusses utilizing gene expression profiling (GEP) to risk stratify tumors in cutaneous squamous cell carcinoma patients.